Novartis Pharmaceuticals Human Resources Generalist Salaries in New York
The average Novartis Pharmaceuticals Human Resources Generalist in New York earns an estimated $106,499 annually, which includes an estimated base salary of $96,555 with a $9,944 bonus. Novartis Pharmaceuticals' Human Resources Generalist compensation is $4,275 more than the US average for a Human Resources Generalist. Human Resources Generalist salaries at Novartis Pharmaceuticals in New York can range from $60,000 - $145,200.
In New York, The HR Department at Novartis Pharmaceuticals earns $10,496 more on average than the Marketing Department.
Last updated 2 years ago.
- $96,555
- avg. base
- $9,944
- avg. bonus
Human Resources Generalist Salaries at Novartis Pharmaceuticals
In New York, Human Resources Generalists earn $1,913 more than HR Managers, and $56,810 less than Directors of HR.
Compensation at Novartis Pharmaceuticals by Department
In New York, The HR Department averages $10,496 more than the Marketing Department, and $5,471 less than the Business Development Department
Human Resources Generalist Compensation by Gender (All Companies)
The average female Human Resources Generalist at companies similar size to Novartis Pharmaceuticals reported making $116,859, while the average male Human Resources Generalist at similar sized companies reported making $136,237.
Human Resources Generalist Compensation by Ethnicity (All Companies)
The average Native American Human Resources Generalist at companies similar size to Novartis Pharmaceuticals reported making $160,000, while the average Caucasian Human Resources Generalist at similar sized companies reported making $114,466.
How Human Resources Generalists at Novartis Pharmaceuticals Rate Their Compensation
The majority of Human Resources Generalists at Novartis Pharmaceuticals believe they're compensated fairly. 100% of Human Resources Generalists at Novartis Pharmaceuticals say they receive annual bonuses, and the vast majority (79%) are satisfied with their benefits. See more compensation ratings at Novartis Pharmaceuticals
